sellModerate cluster of 4
Thomas Patrick Kelly sold $47k of DCPH
Chief Financial Officer at Deciphera Pharmaceuticals, Inc.. 3,010 shares at an average of $15.62, traded Feb 16, 2024, filed Feb 20, 2024.
Warning score
43Value
$47k
3,010 shares
Holdings after
80,350
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +6Trade size$47k at market
- 0Share of holdings soldSold 3.6% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-017091, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 15, 2024 | AGrant or award Common Stock | +17,275 | $0.00 | $0 | 83,360 | Feb 20, 2024 |
| Feb 16, 2024 | SOpen-market sale Common Stock | -3,010 | $15.62 | $47k | 80,350 | Feb 20, 2024 |
| Feb 15, 2024 | AGrant or award Stock Option (Right to Buy)derivative | +69,100 | $0.00 | $0 | 69,100 | Feb 20, 2024 |
Related signals
Other insiders at Deciphera Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Deciphera Pharmaceuticals, Inc. | Jama Pitman SVP, Chief Development Officer | $35k 2,267 shares | -3% | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | Matthew L Sherman EVP & Chief Medical Officer | $41k 2,615 shares | -2% | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | Daniel C. Martin Chief Commercial Officer | $35k 2,267 shares | -4% | |
| 30Weak | Deciphera Pharmaceuticals, Inc. | Daniel C. Martin Chief Commercial Officer | $23k 1,624 shares | -3% | |
| 43Moderate | Deciphera Pharmaceuticals, Inc. | Thomas Patrick Kelly Chief Financial Officer | $35k 2,435 shares | -4% | |
| 30Weak | Deciphera Pharmaceuticals, Inc. | Jama Pitman SVP, Chief Development Officer | $23k 1,624 shares | -3% | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | Matthew L Sherman EVP & Chief Medical Officer | $35k 2,435 shares | -3% | |
| 36Weak | Deciphera Pharmaceuticals, Inc. | Matthew L Sherman EVP & Chief Medical Officer | $43k 2,792 shares | -3% | |
| 35Weak | Deciphera Pharmaceuticals, Inc. | Daniel C. Martin Chief Commercial Officer | $27k 1,727 shares | -3% | |
| 43Moderate | Deciphera Pharmaceuticals, Inc. | Thomas Patrick Kelly Chief Financial Officer | $43k 2,792 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.